Loading...
01/11 11:50
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Net Revenue (Q3 2025) $4.8 million, a 35% increase year-over-year. The increase was driven by strong growth in programmatic business and significant growth in service revenue.
Gross Margins (Q3 2025) 61%, consistent with 61% in Q3 2024. This reflects an increase in inventory handling expenses, including tariffs, mostly offset by a reduction in inventory reserve adjustments.
Research and Development Expenses (Q3 2025) $338,000, compared to $188,000 in Q3 2024, an increase due to higher accrual for employee bonuses and an increase in headcount.
Sales, General and Administrative Expenses (Q3 2025) $2.2 million, compared to $1.7 million in Q3 2024, a 30% increase due to higher sales commissions from increased revenue and higher accrual of employee bonuses.
Net Income (Q3 2025) $337,000, compared to $183,000 in Q3 2024, marking a significant increase and the fifth consecutive quarter of profitability.
Adjusted EBITDA (Q3 2025) $418,000, compared to $295,000 in Q3 2024, reflecting improved profitability.
Net Cash Provided by Operating Activities (Q3 2025) $99,000, compared to net cash used of $623,000 in Q3 2024, an improvement of $722,000 primarily due to positive net income offset by an increase in accounts receivable.
Net Revenue (9 months ending September 30, 2025) $14.1 million, a 37% increase year-over-year, driven by strong growth in programmatic and emergency response business, as well as significant growth in service revenue.
Gross Margins (9 months ending September 30, 2025) 63%, compared to 61% in the prior year period, driven by lower product costs from a favorable product mix and a reduction in inventory reserve adjustments.
Sales, General and Administrative Expenses (9 months ending September 30, 2025) $6.7 million, a 15% increase year-over-year due to higher sales commission expense, increased employee bonus accruals, and higher stock-based compensation expense.
Net Income (9 months ending September 30, 2025) $1.1 million, compared to a net loss of $0.3 million in the prior year period, reflecting a significant improvement.
Adjusted EBITDA (9 months ending September 30, 2025) $1.4 million, compared to $67,000 in the prior year period, showing substantial growth.
Cash Balance (as of September 30, 2025) $5.2 million, compared to $3.8 million as of December 31, 2024, reflecting an increase while remaining debt-free.
PFAS removal solution: Launched and now in the field, targeting new verticals such as municipalities, dialysis centers, and labs. Early response is encouraging.
Market expansion: Expanded into dental, municipal, and government facilities with operational discipline and strategic focus.
Filtration installation program: Continues to drive growth with increased reorder rates, deeper engagement, and stronger customer loyalty.
Programmatic business: Achieved the highest level in company history, contributing to consistent recurring revenue streams.
Strategic focus: Focused on scaling successful operations, pursuing new opportunities, and maintaining financial discipline to sustain growth and broaden market reach.
Regulatory Requirements: The company faces challenges from existing and new regulatory requirements, which could impact its business operations and financial performance.
Inventory Handling Expenses: Increased inventory handling expenses, including tariffs, have affected gross margins, though partially offset by reductions in inventory reserve adjustments.
Sales and Administrative Costs: Higher sales commissions and employee bonus accruals have led to increased SG&A expenses, which could pressure profitability if not managed effectively.
Accounts Receivable: An increase in accounts receivable has offset positive net income, potentially impacting cash flow management.
Future Growth and Market Expansion: Nephros is optimistic about sustaining growth and broadening market reach, supported by strong customer retention, a record number of active sites, and new innovations already in the market. The company is expanding into dental, municipal, and government facilities with operational discipline and strategic focus.
PFAS Removal Solution: The company has launched its PFAS removal solution, targeting new verticals such as municipalities, dialysis centers, and labs. This is expected to be a growth engine for years to come.
Financial Position and Innovation Pipeline: Nephros has a strong balance sheet with zero debt and a robust innovation pipeline, positioning the company to deliver strong value in the quarters ahead.
The selected topic was not discussed during the call.
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
The earnings call reveals strong financial performance with increased revenue, improved margins, and positive net income, despite some economic and competitive pressures. The company's strategic initiatives, including market expansion and digital tool development, are progressing well. The Q&A section indicates potential growth opportunities, although some responses were vague. The absence of shareholder return plans is a minor negative. Overall, the positive financial results and strategic growth initiatives suggest a positive stock price movement.
The earnings call reflects strong financial performance with a significant increase in net income and improved margins, despite some economic concerns. The Q&A section reveals optimism in new product opportunities and market expansion, though management was vague on certain details. Overall, the positive financial results and growth potential suggest a likely positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
